ICON Acquires PMG Research, Inc.
07 Dezembro 2015 - 11:30AM
Business Wire
Acquisition enhances ICON’s site and patient
engagement capabilities
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
acquisition of PMG Research, Inc., an integrated network of
clinical research sites operating from 12 metropolitan areas
throughout the US. The acquisition will enhance ICON’s ability to
access and engage with investigator sites and patients, helping
customers to reduce the overall time and cost associated with drug
development.
PMG Research is an integrated network of clinical research sites
consisting of 48 physician practices and large multi-specialty
healthcare institutions throughout North Carolina, South Carolina,
Tennessee and Illinois. PMG Research conducts clinical trials in
all major therapeutic areas with particular experience in
cardiology, dermatology, endocrinology, gastroenterology, men’s
health, neurology, pulmonology, rheumatology, vaccine, and women’s
health trials. In addition to a proprietary research database of
clinical trial participants, PMG Research also has access to over 2
million active patient lives via electronic health records through
their unique partnerships with healthcare systems and community
physician practices.
Commenting on the acquisition, Ciaran Murray said: “Enrolling
and engaging patients in clinical trials is a key challenge within
drug development. Leveraging PMG Research’s network, we will help
customers to enhance clinical trial feasibility and improve patient
enrolment timelines whilst also giving patients access to a broader
range of care options through clinical trials. Today’s acquisition,
together with our work with IBM Watson on clinical trial matching,
reflects our commitment to enhancing engagement with sites,
patients and healthcare providers to take significant time and cost
from our customers’ development programmes.”
Jennifer Byrne, CEO of PMG Research, states, “ICON shares PMG’s
progressive views and by combining together we can enhance our
ability to scale our know-how, infrastructure, and health care
relationships to bring more of the right trials to the right
patients. Together we will enhance the execution of clinical trials
and deliver greater value for both the industry and health care
systems, forging better and closer connections. The ultimate
beneficiary of this work will be patients through lower cost of
care, improved clinical outcomes and enhanced patient
experiences.”
About PMG Research, Inc.
PMG Research, Inc. is an integrated network of clinical research
facilities with 12 hub supersites located in Champaign, IL; Cary,
Charlotte, Hickory, Raleigh, Rocky Mount, Salisbury, Wilmington,
and Winston-Salem, NC; Charleston, SC; and Bristol and Knoxville,
TN. PMG has conducted over 7,500 research studies for hundreds of
pharmaceutical sponsors and CROs since 1979. PMG’s mission is to
bring clinical research to as many lives as possible while
delivering unparalleled service and exceptional value to clinical
trial partners and stakeholders. Further information is available
at www.pmg-research.com.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 77 locations in 38 countries and has approximately
11,700 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151207005550/en/
ICON Media ContactWeber ShandwickRosie Ireland, +44 (0)
207 067 0190RIreland@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024